Management of Obstructive Uropathy Secondary to Bladder Cancer

Initial Assessment and Decision Framework

The American College of Radiology recommends percutaneous nephrostomy (PCN) or antegrade ureteral stenting as the preferred initial approach for obstructive uropathy secondary to bladder cancer, with technical success rates approaching 95-100% 1, 2
The presence of obstructive uropathy is an independent predictor of advanced bladder cancer stage, extravesical disease, and poor clinical outcome, according to the European Society for Medical Oncology 3

PCN placement has superior technical success rates (95-100% for dilated systems, 80-90% for non-dilated systems) compared to retrograde stenting in malignant obstruction, as stated by the Society of Interventional Radiology 1
The American College of Radiology suggests that PCN is particularly effective when tumor involves the ureteral orifice or ureterovesical junction, or when there is extrinsic compression or long strictures 2

For potentially curative treatment candidates, the European Association of Urology recommends radical cystectomy with extended lymphadenectomy after renal function optimization via PCN 4, 3
The American College of Radiology advises that the decision to place PCN in advanced disease requires careful consideration of prognosis and treatment options, with PCN offering limited benefit with median survival of 3-7 months 2

The European Society for Medical Oncology recommends gemcitabine/cisplatin or dose-dense MVAC for cisplatin-eligible patients, and gemcitabine/carboplatin followed by maintenance avelumab for cisplatin-ineligible patients 5, 6

The Society of Interventional Radiology suggests that nephrostomy tubes typically remain until definitive cancer treatment is completed 1
Regular assessment of renal function and monitoring for progressive renal dysfunction despite drainage are crucial, as stated by the American College of Radiology 1